Seaport Therapeutics (SPTX) is a Healthcare company in the Biotechnology industry. It has a market capitalization of $1.15B and a free-cash-flow yield of -9.4%. Nama's AI scorecard rates it Sell, 2.5 out of 10.
AI scorecard
Sell · 2.5/10
Clearly negative, short of the bottom band. As of Nov 7, 2026.
Shariah screen
Can't Tell
A figure the screen needs is missing, so it can't tell.
Off its high
-24.2%
How far the last close sits under the highest price of the past five years.
Market cap
$1.15B
Trailing P/E
—
Price / book
—
Price / sales
—
FCF yield
-9.4%
Dividend yield
—
Gross margin
0.0%
Operating margin
0.0%
Net margin
0.0%
Revenue growth (YoY)
—
Revenue growth (3-yr annual)
—
EPS growth (YoY)
—
FCF/share growth (YoY)
—
Beta
—
Exchange
NASDAQ
Sector
Healthcare
Industry
Biotechnology
SPTX earnings
Next report: Nov 12, 2026 (Q3 2026, EPS estimate -$0.56).
Beat the EPS estimate in 0 of 2 recent quarters.
Quarter
Reported
EPS
Estimate
Surprise
Revenue
Q2 2026
Aug 3, 2026
-$1.78
-$0.66
-169.7%
—
Q1 2026
Jun 8, 2026
-$10.34
-$3.88
-166.5%
$0
SPTX analyst price target
Median target $35.00 from 8 analysts, ranging $28.00 – $50.00.
Nama's AI scorecard currently rates Seaport Therapeutics Sell (2.5 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
When does SPTX report earnings?
Seaport Therapeutics's next scheduled report is on Nov 12, 2026. Analysts expect EPS of -$0.56.
What is the SPTX price target?
The median analyst price target from 8 analysts is $35.00, with a range of $28.00 – $50.00.
Is SPTX Shariah compliant?
Nama's AAOIFI-style screen reads Seaport Therapeutics as Can't Tell. A figure the screen needs is missing, so it can't tell.